| 赛利司他（ATL-962）、利莫那班和赛尼可的研发与市场趋势 |
| |
| 引用本文： | 阎家麒,高荣,谢建平,Jianping.赛利司他（ATL-962）、利莫那班和赛尼可的研发与市场趋势[J].化工时刊,2008,22(2):72-73. |
| |
| 作者姓名： | 阎家麒 高荣 谢建平 Jianping |
| |
| 作者单位： | 泰州市今朝伟业精细化工有限公司,江苏,泰州,225327 |
| |
| 摘 要： | 本文阐述了赛利司他、利莫那班和赛尼可3种新减肥药物的研发和市场趋势，同时对这3种减肥药物作了疗效比较，并对各种药物的优缺点进行了分析。赛利司他和利莫那班蕴藏着巨大商机，尤其是脂肪酶抑制剂赛利司他。
|
| 关 键 词： | 赛利司他 利莫那班赛尼可 减肥药物 |
| 收稿时间： | 2007-08-27 |
| 修稿时间： | 2007年8月27日 |
Research and Development and Market Trends of Anti-obesity Drugs such as Cetilistat(ATL-962),Rimonabant and Xenical |
| |
| Yan Jiaqi,Gao Rong,Xie,Jianping.Research and Development and Market Trends of Anti-obesity Drugs such as Cetilistat(ATL-962),Rimonabant and Xenical[J].Chemical Industry Times,2008,22(2):72-73. |
| |
| Authors: | Yan Jiaqi Gao Rong Xie Jianping |
| |
| Affiliation: | Yan Jiaqi Gao Rong Xie Jianping (Taizhou Jinzhaoweiye Fine Chernieals Co., Ltd., Jiangsu Taizhou 225327) |
| |
| Abstract: | The research and development of three new anti-obesity drugs such as Cetilitat（ATL-962）, Rimonabant and Xenical and their current market trends were presented. Meanwhile, the three drugs effects in administration and the advantages and disadvantages of each were analyzed. Cetilitat （ATL-962）, Rimonabant had the potential to greatly enhance the market opportunity for lipase inhibitors and thus the potential for Cetilistat. |
| |
| Keywords: | Cetilitat（ATL-962） Rimonabant Xenical anti-obesity drugs |
| 本文献已被 维普 万方数据 等数据库收录！ |
